Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. Deniz Tural , Ömer Fatih Ölmez , Ahmet Taner Sümbül , Mehmet Artaç , Nail Özhan , Emre Akar , Burcu Çakar , Osman Köstek , Meltem Ekenel , Mustafa Erman , Hasan Şenol Coşkun , Fatih Selçukbiricik , Özge Keskin , Fatma Paksoy Türköz , Kerem Oruç , Selami Bayram , Uğur Yılmaz , İrem Bilgetekin , Birol Yıldız , Mehmet Ali Nahit Şendur , Nail Paksoy , Ahmet Dirican , Dilek Erdem , Meltem Selam , Özgür Tanrıverdi , Semra Paydaş , Zuhat Urakçı , Elif Atağ , Sabri Güncan , Yüksel Ürün , Ali Alkan , Ali Osman Kaya , Deniz Tataroğlu Özyükseler , Halil Taşkaynatan , Mustafa Yıldırım , Müge Sönmez , Tuğba Başoğlu , Şeyda Gündüz , Saadettin Kılıçkap JOURNAL OF CLINICAL ONCOLOGY（2021）
摘要
Atezolizumab is effective and well-tolerated in patients with metastatic urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting.
更多 查看译文
关键词
Atezolizumab, Bladder cancer, Immunotherapy, Urothelial carcinoma
AI 理解论文
溯源树
样例
